Kolexia
Perol David Santé publique
Perol David
Santé publique
Centre Léon-Bérard
Lyon, France
321 Activités
567 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Carcinomes Métastase tumorale Récidive tumorale locale Néphrocarcinome Sarcomes Carcinome pulmonaire non à petites cellules Tumeurs du poumon Tumeurs du rein

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Cassier Philippe
Cassier Philippe
Centre Léon-Bérard, Lyon, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Takeda Pharmaceutical
6 collaboration(s)
Dernière en 2023
KEPHREN PUBLISHING
4 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023
Edimark
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
European journal of cancer (Oxford, England : 1990)   01 mars 2024
CaboPoint: A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
Essai Clinique (Ipsen)   22 février 2024
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
BMC cancer   01 février 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Science translational medicine   24 janvier 2024
PRadR: A Multicentric, Single Arm, Open-label, Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
Essai Clinique (Centre Léon-Bérard)   17 novembre 2023
LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023